Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
Completed · Phase 2 · Has a placebo group
Conditions studied: Schizophrenia
In brief
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with placebo in adult subjects with a primary diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of symptoms.
Key facts
- Study ID
- NCT05545111
- Run by
- Neurocrine Biosciences
- People needed
- 210
- Starts
- 2022-10-04
- Expected to finish
- 2024-07-10
- Last updated by the study team
- 2025-07-11
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Neurocrine Clinical Site — Little Rock, Arkansas, United States
- Neurocrine Clinical Site — Rogers, Arkansas, United States
- Neurocrine Clinical Site — Lemon Grove, California, United States
- Neurocrine Clinical Site — Pico Rivera, California, United States
- Neurocrine Clinical Site — San Diego, California, United States
- Neurocrine Clinical Site — Torrance, California, United States
- Neurocrine Clinical Site — Miami Lakes, Florida, United States
- Neurocrine Clinical Site — Oakland Park, Florida, United States
- Neurocrine Clinical Site — Gaithersburg, Maryland, United States
- Neurocrine Clinical site — St Louis, Missouri, United States
- Neurocrine Clinical Site — Berlin, New Jersey, United States
- Neurocrine Clinical Site — North Canton, Ohio, United States
- Neurocrine Clinical Site — Austin, Texas, United States
- Neurocrine Clinical Site — DeSoto, Texas, United States
- Neurocrine Clinical Site — Richardson, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.